Selective muscarinic receptor antagonists for airway diseases

Curr Opin Pharmacol. 2001 Jun;1(3):223-9. doi: 10.1016/s1471-4892(01)00040-6.

Abstract

Airway tone and airway hyperreactivity are mediated by the parasympathetic nerves that release acetylcholine onto muscarinic receptors (M1-M5). Stimulation of M1 and M3 muscarinic receptors causes bronchoconstriction. The M1 muscarinic receptor is excitatory, and facilitates neuronal transmission at the parasympathetic ganglion. The M2 receptor is an inhibitory prejunctional autoreceptor. The discovery of discrete muscarinic receptor subtypes prompted development of selective muscarinic receptor antagonists. Selective M3 receptor antagonists and antagonists selective for M1 and M3 receptors have recently entered clinical trials and offer much promise for the treatment of airways diseases.

Publication types

  • Review

MeSH terms

  • Animals
  • Bronchial Hyperreactivity / prevention & control
  • Humans
  • Muscarinic Antagonists / therapeutic use*
  • Parasympathetic Nervous System / drug effects
  • Parasympathetic Nervous System / physiology
  • Receptors, Muscarinic / drug effects
  • Respiratory System / innervation
  • Respiratory Tract Diseases / drug therapy*
  • Respiratory Tract Diseases / pathology

Substances

  • Muscarinic Antagonists
  • Receptors, Muscarinic